Iaso Ventures
Venture firm and venture-studio hybrid focused on investing in and building companies in behavioral health, neuroscience, and data-driven therapeutic development. Activities include venture investing, a venture studio program, sector-focused thought leadership and event participation, and collaborations that span digital biomarkers, sensors/wearables, remote patient monitoring, and machine-learning applications to clinical data.
Industries
Nr. of Employees
small (1-50)
Iaso Ventures
Services
Early-stage investment and operator-led portfolio management focused on behavioral health and neuroscience startups.
Cohort-based studio activities providing resources and operational support to launch and accelerate startups.
Hosting and co-producing panel discussions, webinars, podcasts, and conference presentations on precision medicine and digital health topics.
Early-stage investment and operator-led portfolio management focused on behavioral health and neuroscience startups.
Cohort-based studio activities providing resources and operational support to launch and accelerate startups.
Hosting and co-producing panel discussions, webinars, podcasts, and conference presentations on precision medicine and digital health topics.
Expertise Areas
- Venture investment in behavioral health and neuroscience
- Venture studio and startup incubation
- Digital health and digital therapeutics
- Neurotechnology and neuromonitoring
Key Technologies
- Digital biomarkers
- Remote patient monitoring
- Sensors and wearable devices
- Connected diagnostics (IoT)
News & Updates
Recurring series on precision medicine produced in collaboration with a law firm to discuss technological and legal developments.
Keynote presentation on emerging trends in health-tech with emphasis on digital biomarkers and therapeutics.
Profiled as an example of disease-area-focused venture funds and discussion of firm strategy and fundraise.
Recognition from the Massachusetts Innovation Network for the Iaso Venture Studio.
Publication of a manuscript applying machine learning to clinical laboratory data to predict near-term relapse in patients receiving medication for opioid use disorder.
Recurring series on precision medicine produced in collaboration with a law firm to discuss technological and legal developments.
Keynote presentation on emerging trends in health-tech with emphasis on digital biomarkers and therapeutics.
Profiled as an example of disease-area-focused venture funds and discussion of firm strategy and fundraise.
Recognition from the Massachusetts Innovation Network for the Iaso Venture Studio.
Publication of a manuscript applying machine learning to clinical laboratory data to predict near-term relapse in patients receiving medication for opioid use disorder.